Treatment of the Overactive Bladder Syndrome: A Delphi Study

Development of a Flowchart Reflecting the Current Attitude and Approach Towards the Idiopathic Overactive Bladder Treatment in Belgium: A Delphi Study

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04300400

Enrollment

Registered

2020-03-09

Start date

2018-10-16

Completion date

2019-09-10

Last updated

2023-01-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Overactive Bladder Syndrome

Keywords

Overactive bladder Syndrome, Delphi study, Treatment algorithm

Brief summary

Idiopathic overactive bladder syndrome (iOAB) is a prevalent condition in urological practice. The variability in management between specialists and between centers remains high. Even guidelines are not always clear on the treatment management of drug therapy resistant OAB. Standardization in OAB treatment is needed.

Detailed description

Guidelines on the overactive bladder syndrome (European Association of Urology, American Urology Association and International Consultation on Incontinence) are comparable but remain vague mainly on the level between conservative and major surgery. They do not specify combinations of medications and do not distinguish between intradetrusor botulinum toxin injections (BTX) and sacral neuromodulation (SNM) because of lack of evidence. To reduce the variability in the treatment management of OAB, standardization is needed. By use of a Delphi technique, the current perception of Belgian urologists towards the most appropriate treatment approach for idiopathic OAB (iOAB) was explored. Based on these results a practical treatment algorithm for its use in daily clinical practice could be developed.

Interventions

OTHERDelphi questionnaire

Statements on OAB topics, rated along their level of appropriateness on a scale from 1 to 9. Multiple rounds are organised to reach consensus on a topic.

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* Profession: MD, Urologist * Member of the working group of Functional Urology

Exclusion criteria

* Retirement * Non-operative as an urologist.

Design outcomes

Primary

Measure	Time frame	Description
Degree of consensus on the level of appropriateness	8 months	No consensus, trend towards consensus or consensus

Countries

Belgium

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026